摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-4-(2,2,2-trifluoroethoxy)pyrimidine

中文名称
——
中文别名
——
英文名称
2-chloro-4-(2,2,2-trifluoroethoxy)pyrimidine
英文别名
——
2-chloro-4-(2,2,2-trifluoroethoxy)pyrimidine化学式
CAS
——
化学式
C6H4ClF3N2O
mdl
——
分子量
212.559
InChiKey
JBEXWWMOEXZMLL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    2-chloro-4-(2,2,2-trifluoroethoxy)pyrimidine三甲胺 作用下, 以 甲苯 为溶剂, 以77%的产率得到2-cyano-4-(2,2,2-trifluoroethoxy)-pyrimidine
    参考文献:
    名称:
    Fungicides
    摘要:
    具有公式(I)的化合物##STR1##其中R.sup.1,R.sup.2和A的定义如规范中所述。这些化合物可用作杀真菌剂。
    公开号:
    US05439910A1
  • 作为产物:
    描述:
    2,4-二氯嘧啶2,2,2-三氟乙醇 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.5h, 以78%的产率得到2-chloro-4-(2,2,2-trifluoroethoxy)pyrimidine
    参考文献:
    名称:
    Thieno-pyrimidine compounds having fungicidal activity
    摘要:
    本发明涉及具有杀真菌活性的噻吩[2,3-d]-嘧啶化合物。
    公开号:
    US20070093498A1
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING
    申请人:IFM DUE INC
    公开号:WO2020252240A1
    公开(公告)日:2020-12-17
    This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    本公开涉及抑制(例如,拮抗)干扰素基因激活因子(STING)的化学实体(例如,化合物或药用可接受的盐,和/或水合物,和/或共晶,和/或化合物的药物组合)。所述化学实体是有用的,例如,用于治疗在受试者(例如,人)中增加(例如,过量)STING激活(例如,STING信号传导)有助于病理和/或症状和/或进展的状况、疾病或失调(例如,癌症)。本公开还涉及含有相同成分的药物组合物以及使用和制备相同成分的方法。
  • HETEROCYCLIC AMINE DERIVATIVES
    申请人:Galley Guido
    公开号:US20120245172A1
    公开(公告)日:2012-09-27
    The present invention relates to compounds of formula I wherein A, B, X, Y, Ar, R 1 , R 2 , R′, m and n are as defined herein and to pharmaceutical active acid addition salts thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    本发明涉及式I的化合物,其中A、B、X、Y、Ar、R1、R2、R′、m和n的定义如本文所述,并且涉及其药用活性酸盐。式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力,特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍(ADHD)、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、以及代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍、以及心血管疾病。
  • [EN] HETEROCYCLIC AMINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINES HÉTÉROCYCLIQUES
    申请人:HOFFMANN LA ROCHE
    公开号:WO2012126922A1
    公开(公告)日:2012-09-27
    The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, -O-CH2-C3-6-cycloalkyl, -O-(CH2)2-O-lower alkyl, S(O)2CH3, SF5, -C(O)NH-lower alkyl, phenyl, -O-pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen, or is benzyl, oxetanyl or furanyl; m Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo[d][1.3]dioxolyl, 5,6,7,8- tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl, or 1,3,4-oxadiazolyl; Y is a bond, -CH2-, -CH2CH2-, -CH(CF3)- or -CH(CH3)-; R2 is hydrogen or lower alkyl; A is CR or N; and R is hydrogen, cyano, halogen or lower alkyl; R' is hydrogen or halogen; with the proviso that when R' is halogen, then A is CH; B is CH or N; n is 0, 1 or 2; X is a bond, -CH2- or -O-; pharmaceutical active acid addition salts thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    本发明涉及以下式(I)的化合物,其中R1是氢、低碳基、卤素、被卤素取代的低碳基、低烷氧基、被卤素取代的低烷氧基、氰基、硝基、C3-6环烷基、-CH2-C3-6环烷基、-O-CH2-C3-6环烷基、-O-(CH2)2-O-低碳基、S(O)2CH3、SF5、-C(O)NH-低碳基、苯基、-O-嘧啶基,或是被低烷氧基取代的被卤素取代的苯基、或者是苄基、氧杂环戊二烯基或呋喃基;m Ar是芳基或杂芳基,选自苯基、萘基、嘧啶基、吡啶基、苯并噻唑基、喹啉基、喹唑啉基、苯并[d][1.3]二噁基、5,6,7,8-四氢喹唑啉基、吡唑基、吡嗪基、吡啶啉基或1,3,4-噁二唑基;Y是键、-CH2-、-CH2CH2-、-CH(CF3)-或-CH(CH3)-;R2是氢或低碳基;A是CR或N;R是氢、氰基、卤素或低碳基;R'是氢或卤素;但是如果R'是卤素,则A是CH;B是CH或N;n是0、1或2;X是键、-CH2-或-O-;以及它们的药用活性酸盐。现已发现,式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力,特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍(ADHD)、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢障碍,如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍,以及心血管疾病。
  • Thieno-pyrimidime compounds having fungicidal activity
    申请人:Dow AgroSciences LLC
    公开号:EP2078721A2
    公开(公告)日:2009-07-15
    The present invention relates to thieno[2,3-d]-pyrimidine compounds of Formula (I) having fungicidal activity.
    本发明涉及具有杀菌活性的式(I)噻吩并[2,3-d]嘧啶化合物。
  • WO2007/46809
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多